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ABSTRACT: Recurrent miscarriage (RM) is a multifac-
torial disorder with acknowledged genetic heritability that
affects3% of couples aiming at childbirth. As copy num-
ber variants (CNVs) have been shown to contribute to
reproductive disease susceptibility, we aimed to describe
genome-wide profile of CNVs and identify common rear-
rangements modulating risk to RM. Genome-wide screen-
ing of Estonian RM patients and fertile controls identified
excessive cumulative burden of CNVs (5.4 and 6.1 Mb
per genome) in two RM cases possibly increasing their in-
dividual disease risk. Functional profiling of all rearranged
genes within RM study group revealed significant enrich-
ment of loci related to innate immunity and immunoregu-
latory pathways essential for immune tolerance at fetoma-
ternal interface. As a major finding, we report a multicopy
duplication (61.6 kb) at 5p13.3 conferring increased ma-
ternal risk to RM in Estonia and Denmark (meta-analysis,
n = 309/205, odds ratio = 4.82, P = 0.012). Compari-
son to Estonian population-based cohort (total, n = 1000)
confirmed the risk for Estonian female cases (P = 7.9 ×
10−4). Datasets of four cohorts from the Database of Ge-
nomic Variants (total, n = 5,846 subjects) exhibited sim-
ilar low duplication prevalence worldwide (0.7%–1.2%)
compared to RM cases of this study (6.6%–7.5%). The
CNV disrupts PDZD2 and GOLPH3 genes predomi-
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nantly expressed in placenta and it may represent a novel
risk factor for pregnancy complications.
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cals, Inc.∗
KEY WORDS: recurrent miscarriage; fetomaternal inter-
face; immune dysfunction; placenta; GOLPH3; PDZD2
Introduction
Miscarriage is the most common pregnancy complication af-
fecting up to 15% of all clinically recognized pregnancies [Stirrat,
1990]. The risk of miscarriage increases with age and is enhanced
by a trend in developed countries to postpone childbearing to late
30s and early 40s with declined fertility rates [Nybo Andersen et al.,
2000; Group TECW, 2010]. Recurrent miscarriage (RM), defined
as 3 consecutive pregnancy losses before 22nd gestational week,
is a heterogeneous disorder affecting up to 3% of couples aiming
at childbirth [Christiansen et al., 2008]. It is a distressing condition
for affected couples as each subsequentmiscarriage leads to elevated
risk of experiencing further pregnancy loss [Ogasawara et al., 2000]
and increased probability of other pregnancy complications such as
preterm delivery or small for gestational age newborns [Jivraj et al.,
2001; van Oppenraaij et al., 2009]. Although a spectrum of fac-
tors is known to increase the risk to RM, including immune system
dysfunction and thrombophilic disorders, the underlying etiology
remains undetermined in about half of the cases [Rai and Regan,
2006; Allison and Schust, 2009].
A familial segregation of RM has been observed highlighting the
contribution of the genetic predisposition to the disease [Chris-
tiansen et al., 1990; Kolte et al., 2011]. So far, majority of the studies
focusing on the genetic susceptibility to RM have addressed single
nucleotide polymorphisms (SNP) in more than 100 RM candidate
genes, often providing conflicting results and no identified risk vari-
ants with confirmed strong effect [Nagirnaja et al., 2012; Rull et al.,
2012, 2013]. More recently, paternal DNA fragmentation, epige-
netic disturbances, and DNA copy number variants (CNVs) have
C© 2014 The Authors. ∗Human Mutation published by Wiley Periodicals, Inc.
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Figure 1. Study design and procedures. Following initial CNV discovery phase in a subsample of Estonian subjects, whole-genome profiling
of all identified CNVs and association study of discrete CNV regions were performed. Three CNVRs were taken forward to be analyzed in the
full Estonian sample set to identify potential risk-conferring rearrangements. For the duplication at 5p13.3, genetic Association testing 1 in the
full Estonian sample and Association testing 2 using Estonian cohort (EGCUT) control samples were then undertaken, followed by Replication
study in the Danish sample set. Comparative prevalence data from the Database of Genomic Variants (DGV) were collected followed by detailed
duplicationbreakpoint characterizationandconfirmationof duplicationcarriership of all RMcasesand fertile controls of the studyusingduplication-
specific junction-spanning PCR. Expression profiling in human tissues was performed for the genes PDZD2 and GOLPH3 disrupted by the 5p13.3
rearrangement.
been suggested to modify predisposition to RM [Rajcan-Separovic
et al., 2010; Uuskula et al., 2010; Robinson et al., 2012]. CNVs
represent deletions or duplications of >50 bp DNA sequence that
disrupt around 13% of RefSeq genes [McCarroll et al., 2008; Zhang
et al., 2009; Conrad et al., 2010]. It has been estimated that 17.7%
of variability in gene expression may be attributed to these DNA
variants and, subsequently, a growing number of genic CNVs and
increased global burden of CNVs have been linked to several com-
plex disorders [Stranger et al., 2007; Zhang et al., 2009; Girirajan
et al., 2011]. Studies focusing on structural variation predisposing to
pregnancy complications have been scarce and represent single re-
ports addressing disease-associated CNVs in unexplained stillbirths
and preeclampsia [Harris et al., 2011; Zhao et al., 2012, 2013]. A sin-
gle study has addressed the contribution of CNVs in RMusing array
comparative genomic hybridization to screen 26 placentas fromRM
pregnancies for rare CNVs to identify candidate genes, which could
be causative for the specific miscarriage [Rajcan-Separovic et al.,
2010].
In the current genome-wide study, we set forward to address the
role of CNVs in predisposing to RM among the couples of unex-
plained RM from Estonia and Denmark. The collaborative effort
involved 558 RM cases with 3 consecutive miscarriages (in total,
309 RM female and 249 male partners), fertile multiparous control
women (n = 205), and population-based samples from Estonian
Biobank, Estonian Genome Center, University of Tartu (EGCUT;
n = 1,000).We aimed to (A) assess the contribution of genome-wide
burden of CNVs and (B) identify and characterize novel common
CNVs in modulating the risk of RM (Fig. 1). We determined exces-
sive cumulative burden of all CNVs (5.4 and 6.1Mb per genome) in
two RM cases possibly increasing their individual risk of the disease.
The genomic CNV profile within the RM study group was signifi-
cantly enriched for CNVs predominantly affecting genes related to
innate immunity signaling and immunoregulatory interactions.As a
major finding, we identified amulticopy duplication CNV (61.6 kb)
at 5p13.3 conferring high, almost fivefold increased maternal risk
of RM and disrupting two novel RM candidate genes, PDZD2
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and GOLPH3, associated with pregnancy maintenance for the first
time.
Materials and Methods
Study Subjects
RM cases and fertile control samples
RM cases and fertile controls have been recruited in two North
European countries Estonia and Denmark, and the applied sample
sets have been well characterized and previously exploited in RM
research [Kruse et al., 2004; Rull et al., 2008, 2013; Kolte et al., 2011].
The studywas approved by the Ethics ReviewCommittee onHuman
Research of the University of Tartu, Estonia, and the Danish Central
National Committee on Biomedical Research Ethics.
As both maternal and paternal genetic information determine
the development of the fetus and the placenta, as well as the out-
come of a pregnancy, the patient group consisted of female patients
and their male partners experiencing idiopathic RM (3 consecu-
tive miscarriages before week 22 of gestation without any identified
cause). In total, the current study included 558 RM patients from
Estonia (80 female and 39male partners) andDenmark (229 female
and 210 male cases) (Supp. Table S1). For all recruited cases, known
clinical risk factors of RM have been excluded (Supp. Materials and
Methods). The female patients were further subphenotyped as ei-
ther primary (Estonia, n = 46; Denmark, n = 113) or secondary RM
(Estonia, n = 34; Denmark, n = 116) based on the occurrence of con-
secutive miscarriages either before (if any) live births or following
one or more live births, respectively.
The control group consisted of 205 fertile females from Estonia
(n = 90) and Denmark (n = 115) with no history of miscarriages and
at least two (Denmark) or three (Estonia) successful pregnancies
ending with live birth (Supp. Table S1). Male partners of fertile
female controls were not included into the study due to limited
information on their previous reproductive history.
Population-based cohort samples from Estonian Biobank
(EGCUT)
The carrier status of the identified RM-associated risk CNV at
5p13.3 was additionally determined for population-based cohort
samples (n = 1,000; 504 men, 496 women) drawn from the Estonian
population-based Biobank (EGCUT; www.biobank.ee; Supp. Ma-
terials and Methods) and previously subjected to SNP genotyping
with Human370CNV-Duo SNP array (Illumina Inc., San Diego,
CA) [Nelis et al., 2009] and genome-wide CNV calling (Priit Palta,
unpublished data).
Discovery Phase: Genome-Wide SNP Genotyping and CNV
Detection
The study design is schematically outlined in Figure 1. In the
discovery phase, proportionally one-third subsample (n = 70; fer-
tile controls, n = 27; RM cases, n = 43; Supp. Table S2) of all
Estonian study subjects (n = 209) was genotyped using Illumina
Human370CNV-Quad SNP array (Genotyping Core Facility, Esto-
nian Biocentre). For each sample, calling of CNVs from the result-
ing genome-wide genotyping data was performed in parallel with
two algorithms, QuantiSNP and PennCNV [Colella et al., 2007;
Wang et al., 2007] (Supp. Materials and Methods). The initial CNV
calls from the two algorithms were merged and only CNVs that
were called by both algorithms for the same individual in the same
genomic loci were considered in the subsequent global analysis.
Discrete CNV regions (CNVRs) were defined by merging overlap-
ping CNV calls across all individuals in a study group as described
previously [Redon et al., 2006; Perry et al., 2008]. Genomic distri-
bution of identified CNVRs was visualized using Circos software
(http://circos.ca/) [Krzywinski et al., 2009]. The genome-wide CNV
data of this study have been submitted to the Database of Genomic
Variants (DGV; http://projects.tcag.ca/variation/).
For theEGCUTpopulation-based cohort samples, themicroarray
data were processed in identical manner using parallel analysis of
QuantiSNP and PennCNV and by considering only CNV calls that
were made by both algorithms. Accurate CNV copy number for the
5p13.3 duplication locus was drawn from the QuantiSNP data due
to its higher precision in copy number estimation in this locus.
Functional Enrichment Analysis
In order to acquire the up-to-date genomic annotation data for
functional enrichment analysis, all CNVR breakpoint coordinates
were converted to the latest version of the human reference sequence
(from NCBI36/hg18 to GRCh37/hg19) (Supp. Materials and Meth-
ods). The list of genes within the identified CNV regions (extended
by 10 kb on either side of theCNVR)was then acquired from the En-
sembl database (version 69; http://www.ensembl.org/index.html).
Functional enrichment analysis of subsequent gene sets was
carried out separately for fertile controls and RM patients using
g:Profiler gGOSt web-based software (http://biit.cs.ut.ee/gprofiler/)
[Reimand et al., 2007, 2011] (Supp. Materials and Methods). Two
outlier cases with increased genomic burden of CNVs (RM-M45
and RM-F4) were excluded from the analysis to avoid biased results.
Results of Gene Ontology (GO) and Reactome (REAC) datasets
with up to third relative hierarchy level were taken into account and
enrichment for functional terms was considered significant if the
multiple testing corrected enrichment P-value was <0.05.
Prioritization of CNVRs for Experimental Confirmation and
Subsequent Analysis
Discrete CNV regions identified in the discovery phase based on
the whole genome SNP array genotyping data (full list of CNVRs in
Supp.Table S3)were selected for experimental confirmationand fur-
ther analysis if the following criteriaweremet:CNVRwas (1)present
in >1 individual (criterion met by 118 out of 423 nonoverlapping
CNVRs), (2) found only among RM patients or overrepresented in
RM patients with odds ratio (OR) 1.5 (45/118 CNVRs), and (3)
intersected with or located in the proximity (up to approximately
200 kb) of biological candidate genes with a potential impact on the
course of pregnancy based on previously published literature (9/45
CNVRs). As our study aimed to identify common rearrangements
predisposing to RM, previous reports in the DGV database for the
prioritized CNVRs of this study were considered as confirmation of
true CNV loci, rather than as an exclusion criterion due to unknown
reproductive success of the genotyped individuals in these reports.
Experimental Copy Number Estimation of Prioritized CNVRs
Using TaqMan qPCR
For experimental testing, TaqMan quantitative PCR (qPCR) was
performed with one assay for seven of the prioritized CNVRs and
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with two assays in parallel for the two largest CNV loci as described
in Supp. Materials and Methods (Supp. Table S4). Ten nanograms
of genomic DNA was amplified using predesigned TaqMan copy
number assays (Applied Biosystems, Foster City, CA; Supp. Table
S5)orpreviouslypublishedTaqManqPCRprimers andFAM-tagged
probe (6p21.33 CNVR; Supp. Table S6) [Parajes et al., 2007]. Copy
number was normalized to the reference RNase P and population-
specific pool of control DNAs (Supp. Materials and Methods). The
diploid genomic copy number was calculated by multiplying the
normalized TaqMan qPCR copy number estimates by two. Because
of limitations of TaqMan qPCR assay to accurately determine very
high diploid copy numbers, individuals with estimated locus copy
number larger than four were assigned into copy number class “>4
copies per diploid genome.”
Experimental Fine Mapping and Characterization of the
5p13.3 Rearrangement
The confirmation of the 5p13.3 duplication endpoints estimated
bySNParraywasperformedwith fourEvaGreenqPCRassays (Supp.
Table S6; Supp. Fig. S1) flanking the predicted breakpoints and
using samples with known 5p13.3 copy number based on the data of
TaqMan qPCR copy number typing (Supp.Materials andMethods).
Copy number was estimated using absolute quantification method
and normalized to the reference gene ALB and population-specific
pool of control DNAs.
The exact position of duplication breakpoint junction in three
5p13.3 duplication carriers was determined using DNA sequencing
by primerwalking and targeting breakpoint junction region (5.8 kb)
defined based on EvaGreen mapping (Supp. Materials and Meth-
ods). A control PCR spanning the identified breakpoint junction of
the 5p13.3 tandem duplication (BP-PCR) was applied to confirm
the duplication carriership in all Estonian and Danish RM case-
control samples previously addressed with TaqMan qPCR (Supp.
Materials and Methods).
The DNA sequences flanking the identified duplication break-
points (±1,000 bp) were screened for repetitive elements us-
ing RepeatMasker software (http://www.repeatmasker.org/) and
searched for the non-B DNA motifs including direct and in-
verted repeats, short-tandem repeats, and cruciform motifs us-
ing non-B DNA motifs search tool (http://nonb.abcc.ncifcrf.gov/
apps/nBMST/default/).
Expression Profile Analysis of PDZD2 and GOLPH3 Genes
The expression analysis was performedusing human tissue cDNA
panels Human MTC panel I and II (BD Biosciences Clontech, Palo
Alto, CA) consisting of pools of samples for each tissue (Supp.
Materials andMethods). The expression profile of theGOLPH3 and
PDZD2 genes was determined with TaqMan qPCR approach using
predesigned TaqMan gene expression assays (Applied Biosystems)
and normalization to the reference transcript of HPRT.
Copy Number Assignment of TaqMan qPCR Values
The copy number assignment for simple deletion and/or dupli-
cation polymorphisms was performed manually, whereas for the
multicopy 5p13.3 locus, average copy number ratio of two TaqMan
assays located within the rearranged region was used for the as-
signment of each sample into a distinct copy number cluster with
k-means clustering method in the statistical package R (ver. 2.15.0;
http://www.R-project.org/) (Supp.Materials andMethods). The re-
sulting grouping was confirmed using EvaGreen qPCR performed
with assay “EvaGr assay 2” located within the rearranged region
(Supp. Fig. S1). Furthermore, the 5p13.3 duplication carriership
was confirmed in all Estonian and Danish RM cases and fertile
controls using the duplication junction-specific control PCR (BP-
PCR). Subsequent groups of carriers versus noncarriers were subject
to genetic association testing (Supp. Fig. S2).
Genetic Association Testing
Genetic association of the 5p13.3 duplication with the clinical
diagnosis of RM was tested using logistic regression model in the
statistical package R (version 2.15.0) in the Estonian andDanish RM
cases/fertile control sample setswith. Subjectswere assignedas either
carriers or noncarriers (wild type) of the tandem duplication. The
obtained population-specific results were subsequently combined
in the classical meta-analysis approach based on effect size estimates
(beta-statistic) and standard errors and performed with the inverse-
variancemethod under fixed-effects model in the statistical package
R. Alternatively, to correct for the asymmetric case/control ratio in
the Estonian and Danish sample sets, a z-score-based meta-analysis
was performed combining the logistic regression P-values, effect
directions, and effective sample sizes using METAL software as de-
scribed by Willer et al. (2010). In Estonians, the RM patient group
was further tested against Estonian Biobank population-based co-
hort samples using logistic regression analysis as described above.
Results with P-values <0.05 were considered significant.
Results
Increased Genomic Burden of CNVs in Two RM Patients
In the discovery phase, the whole-genome screening (Illumina
Human370CNV-Quad SNP array) for structural variants was per-
formed in one-third subset of Estonian case-control samples (n = 70;
Supp. Table S2). On average, 13.3 CNVs were determined per indi-
vidual in RM cases (n = 43) and 12.6 CNVs in fertile female controls
(n = 27). Among all detected CNVs (n = 915) in the full discovery
sample, a 2.1-fold excess of deletions compared to duplications was
observed consistent with previously reported ratios [Redon et al.,
2006; Conrad et al., 2010]. However, the median length of duplica-
tions exceeded significantly the size of deletions (60.8 kb vs. 26.1 kb;
Mann–Whitney U test, P = 1.82 × 10–13).
Genomic burden analysis of all detected CNVs per individual re-
vealed two outlier RM patients RM-F4 and RM-M45 with increased
cumulative size of CNVs exceeding the rest of the RM cases more
than fivefold (6.1Mb and 5.4Mb vs.median of 1.0Mb, respectively)
(Fig. 2; Supp. Fig. S3). The case RM-F4 was the carrier of only het-
erozygous deletions (n = 19; Fig. 2, Supp. Fig. S4A)with themajority
being longer than 100 kb (n = 15; median 313 kb) and deleting al-
together 50 genes. Remarkably, the 5.4 Mb of CNVs (in total, n =
29; Fig. 2, Supp. Fig. S4A) in the case RM-M45 rearranged a total
of 378 genes of which 113 duplicated and five deleted genes were
located within the genomic region of immunoglobulin heavy chain
(IGH) gene cluster at 14q32.33 potentially regulating the immune
function during pregnancy. Additionally, heterozygous deletions of
genes related to spermatogenesis (SOHLH1;MIM#610224,SPATC1;
MIM# 610874) [Goto et al., 2010; Suzuki et al., 2012] and known
RM candidate genes (such as C4A (MIM# 120810), C4B (MIM#
120820), and IGF2 (MIM# 147470)) [Laitinen et al., 1991; Ostojic
et al., 2008]were identified in thismale patient potentially increasing
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Figure 2. Genomic burden of all CNVs in the Estonian discovery phase sample set. Cumulative length of all deletions and duplications is presented
per individual in RM patients (n = 43) and fertile controls (n = 27). The outlier cases with increased cumulative burden of all CNVs (Supp. Fig. S3)
are indicated with asterisk. Female and male patients with identical number codes represent RM couples (e.g., RM-F45 and RM-M45). FFC, fertile
female control; RM-F, female RM patient; RM-M, male RM patient.
the individual’s risk of RM disease. Both patients were from couples
suffering from unexplained primary RMwith no prior live births at
the time of recruitment and had experienced three (RM-M45) or
four (RM-F4) consecutivemiscarriages occurring before gestational
week 12. The available medical records for the male partner RM-
M45 do not report any other diseases. During the postrecruitment
period, the female patient RM-F4 carrying 50 hemizygous genes has
experienced further miscarriages (n = 3) but also live births (n = 2)
as a result of clinical management. Additionally, she has developed
insulin-dependent diabetes mellitus and euthyroid goiters poten-
tially also attributable to the large cumulative burden of deletions.
Functional Profiling of Genes Disrupted by CNVRs Reveals
Enrichment of Immune Signaling Pathways among RM
Cases
The CNVs identified in the discovery phase clustered into 423
nonoverlapping CNVRs in RM cases and fertile controls that were
uniformly distributed across the genome (Supp. Table S3, Supp.
Fig. S4B). Functional profiling analysis of all genesdisruptedby these
CNVRs in either RMpatient group (excluding two outlier cases with
increased CNV burden) or among controls (1151 and 553 genes,
respectively) was undertaken to identify pathways and processes
significantly modulated by the rearrangements. In RM patients,
the analysis specifically highlighted the role of impaired immune
signaling, antigen binding, and immunoregulatory interactions at
the fetomaternal interface in recurrent pregnancy loss (Table 1).
Notably, alterations in the REAC pathways of “innate immunity
signaling” (9.3% of genes rearranged in the pathway, P = 9.15 ×
10–3), “Complement cascade” (13.0% of genes, P = 1.11 × 10–3),
and “Fc gamma receptors interact with antigen-bound IgG” (21.1%
of genes rearranged by CNVs, P = 2.60 × 10–4) were specific to RM
cases as none of the genes belonging to these categories were affected
by structural variants in fertile controls (Table 1).
Among the controls, the analyzed CNVRs likely represent be-
nign rearrangements as only biological pathways of general cellular
function were identified, including signaling of olfactory receptors
(“olfactory signaling pathway,” REAC:381753, P = 9.99 × 10–7), a
large class of genetically diverse proteins in humans known to be
affected by CNVs in healthy individuals [Wong et al., 2007; Hasin-
Brumshtein et al., 2009; Mills et al., 2011].
Experimental Testing of Prioritized CNVRs Detected by SNP
Array
In order to identify common distinct CNV regions increasing
the risk of RM, nine prioritized CNVRs were selected based on the
genome-wide CNV screening results (Supp. Table S3; Supp. Ma-
terials and Methods) and subjected to copy number typing using
TaqMan qPCR in the discovery sample set (n = 70) (see also Fig. 1).
Precise copy number estimation by TaqMan qPCR assays was ob-
served for four prioritized CNVRs, identifying all CNV carriers pre-
dicted based on microarray analysis with no false positives (Supp.
Table S4, Supp. Fig. S5; false negative rate across regions 1.4%).
Three CNV regions— IGKV (immunoglobulin kappa variable clus-
ter at 2p11.2; MIM# 146980), DKK2 (Dickkopf 2 homolog at 4q25;
MIM# 605415), and PDZD2:GOLPH3 (PDZ domain containing 2;
MIM# 610697; golgi phosphoprotein 3 at 5p13.3; MIM# 612207)—
were carried onto the next experimental stage to analyze the full
Estonian RM case-control sample set using the established TaqMan
qPCR approach (Fig. 1). SEPT14CNVR (septin 14 at 7p11.2; MIM#
612140) was excluded from the next stage due to its restricted testis-
specific expression [Peterson et al., 2007].
Although confirmed as copy number variable by TaqMan qPCR,
precise locus copy number estimation of the remaining five pri-
oritized CNVRs (Supp. Table S4) was most likely hindered due to
complex genomic architecture and rearrangements of the region as
also evident based on previous CNV studies (Supp. Fig. S6). Thus,
theseCNVRswere excluded from further genetic association testing.
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Table 1. Pathway Analysis of Genes Affected by CNVs Identified by Genome-Wide Screening of Estonian Discovery Sample Set
Functional category RM casesa Controls
Type ID Name Level Corrected P-valueb Corrected P-valueb
Functional categories significantly enriched in RM cases
GO 0003823 Antigen binding 1 1.16 × 10–4 1.00
REAC 168256 Signaling in immune system 1 1.44 × 10–3 1.00
168249 Innate immunity signaling 1.1 9.15 × 10–3 No genesc
166658 Complement cascade 1.1.1 1.11 × 10–3 No genesc
198933 Immunoregulatory interactions between a lymphoid
and a nonlymphoid cell
1.2 1.61 × 10–4 1.00
199161 Fc gamma receptors interact with antigen-bound IgG 1.2.1 2.60 × 10–4 No genesc
Functional categories significantly enriched in fertile controls
GO 0060089 Molecular transducer activity 1 1.00 2.19 × 10–11
0004871 Signal transducer activity 1.1 1.00 2.19 × 10–11
0071944 Cell periphery 2 1.00 1.28 × 10–7
0005886 Plasma membrane 3 1.00 4.17 × 10–8
0044425 Membrane part 4 1.00 3.27 × 10–6
0031224 Intrinsic to membrane 4.1 1.00 5.36 × 10–6
0016021 Integral to membrane 4.1.1 1.00 5.36 × 10–5
0016020 Membrane 5 1.00 3.90 × 10–4
0004872 Receptor activity 6 1.00 1.16 × 10–15
0038023 Signaling receptor activity 6.1 1.00 2.02 × 10–13
0004888 Transmembrane signaling receptor activity 6.1.1 1.00 1.36 × 10–14
REAC 372790 Signaling by GPCR 1 1.00 5.60 × 10–3
381753 Olfactory signaling pathway 1.1 1.00 9.99 × 10–7
381750 Olfactory receptor-G protein olfactory trimer complex
formation
1.1.1 1.00 9.99 × 10–7
The list of rearranged genes in either patients (n = 43) or controls (n = 27) was subjected to functional enrichment analysis using g:Profiler software (Reimand et al., 2007) and
included Gene Ontology (GO) and Reactome (REAC) functional categories up to third relative hierarchical level. gProfiler performs statistical enrichment analysis to identify
functional groups and/or biological pathways that are significantly overrepresented in the user-provided gene list.
aTwo outlier cases RM-F4 and RM-M45 with increased genomic burden of CNVs (Fig. 2) removed from the analysis.
bMultiple testing corrected enrichment P-value.
cNone of the genes in this functional category were disrupted by CNVs among controls.
GPCR, G protein coupled receptor.
Table 2. Maternal Risk of Recurrent Miscarriage Associated with the PDZD2:GOLPH3 CNV at 5p13.3 in Estonia and Denmark
Women in association testing Association testinga
Controls Number of subjects/carriers (%) Female RM cases Number of subjects/ carriers (%) OR CI (95%) P-value
Association testing 1: full Estonian RM case-control sample
Fertile women 90/1 (1.1) All cases 80/6 (7.5) 7.22 0.85–61.25 0.070
Primary RM 46/4 (8.7) 8.48 0.92–78.18 0.059
Secondary RM 34/2 (5.9) 5.56 0.49–63.45 0.167
Association testing 2: Estonian RM cases versus EGCUT cohort
EGCUT women 496/5 (1.0) All cases 80/6 (7.5) 7.96 2.37–26.75 7.9× 10–4
Primary RM 46/4 (8.7) 9.35 2.42–36.15 0.001
Secondary RM 34/2 (5.9) 6.14 1.15–32.88 0.034
Replication study: Danish RM case-control sample
Fertile women 115/2 (1.7) All cases 229/15 (6.6) 3.96 0.89–17.62 0.071
Primary RM 113/9 (8.0) 4.89 1.03–23.15 0.045
Secondary RM 116/6 (5.2) 3.08 0.61–15.60 0.174
Meta-analysis: Estonian and Danish RM cases and fertile controls
Fertile women 205/3 (1.5) All cases 309/21 (6.8) 4.82 1.42–16.40 0.012
Primary RM 159/13 (8.2) 5.86 1.64–20.94 0.007
Secondary RM 150/8 (5.3) 3.70 0.96–14.25 0.058
Association testing was performed with duplication carriers versus noncarriers as established based on TaqMan qPCR and confirmed by junction-spanning PCR for RM cases
and fertile controls and estimated by QuantiSNP based on SNP genotyping and CNV calling data for EGCUT samples (Supp. Materials and Methods).
aAssociation testing was performed using logistic regression analysis in Estonia and Denmark separately. The results were subsequently combined in the meta-analysis using
inverse-variance method under fixed-effects model. Results with P-value <0.05 were considered significant and are indicated in bold.
Significantly Increased Prevalence of PDZD2:GOLPH3
Duplication in Estonian and Danish RM Cases
Among the three CNVRs (PDZD2:GOLPH3 duplication, IGKV
deletion/duplication, andDKK2 deletion) tested in the full Estonian
sample set (Supp. Table S1), PDZD2:GOLPH3 duplication detected
in up to four copies per diploid genome exhibited the strongest effect
(OR = 7.28) with a higher prevalence of duplication carriers among
the RM cases compared to fertile controls (9/119, 7.6% vs. 1/90,
1.1%, respectively) (Supp. Table S7). The Replication study of the
PDZD2:GOLPH3 CNVR performed in Danish RM cases and fertile
controls (in total, n = 554; Supp. Table S1) confirmed the increased
carrier frequency of the rearrangement (RM patients, 19/439, 4.3%;
controls, 2/115, 1.7%; Table 2). However, a sex-stratified analysis of
the Danish RM patients revealed the higher prevalence only among
the female patients (6.6%) that was comparable to Estonian female
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cases (7.5%) (Fig. 3A, Table 2). The PDZD2:GOLPH3 duplication
reached statistically significant association with an increased risk
of RM (OR = 4.82, P = 0.012) in the meta-analysis combining the
results of the Estonian and Danish female patient-control samples
(in total, cases n = 309, controls n = 205). The high prevalence
of the duplication observed among Estonian male RM partners
was not replicated in Denmark (Supp. Table S8). The observed
differences could be attributed to the different size of the Estonian
and Danish sample sets (n = 208 and n = 558, respectively). These
North European subjects have been recruited according to similar
clinical criteria minimizing the interstudy heterogeneity and used
in parallel in previous collaborative research [Nagirnaja et al., 2012;
Rull et al., 2013].
Notably, the strongest effect of the PDZD2:GOLPH3 CNV was
detected among the subgroupofwomenwithprimaryRM(Estonian
cases: n = 46, CNV carrier frequency 8.7%; Danish, n = 113, 8.0%)
defined as3 consecutive miscarriages and no preceding live births
(meta-analysis, n = 159; OR = 5.86, P = 0.007) (Table 2). A z-score-
basedmeta-analysis correcting for the asymmetric case/control ratio
provided consistent results in association testing including all female
cases (P = 0.011) or only cases of primary RM (P = 0.006; Supp.
Table S9).
The two CNVRs (IGKV locus, Del/Dup; DKK2 locus, Del) with
small differences in carrier frequencies in the full Estonian case-
control sample (Supp. Table S7) likely represent benign common
copy number variation with no major effect on the RM phenotype
in our study.
Low Prevalence of the PDZD2:GOLPH3 Duplication in
Worldwide Cohorts
The high risk of RM associated with the PDZD2:GOLPH3 dupli-
cation was further confirmed when Estonian RM cases were com-
pared to the Estonian Biobank (EGCUT) cohort samples (in total,
n = 1,000) (Table 2). The most significant association among the
subgroups of cases was observed for female patients tested against
female cohort subjects (n = 496; prevalence 1.0%; OR = 7.96, P = 7.9
× 10–4). Importantly, the carrier frequency of the PDZD2:GOLPH3
duplication in the whole EGCUT cohort (9/1,000; 0.9%) was as low
as observed among the Estonian and Danish controls (Table 3) and
similar carrier frequency has been consistently reported for various
large worldwide population-based cohorts in the DGV (sample size
range:n=776–2,026; in total,n= 5846; duplication carrier frequency
from 0.7% to 1.2%) (Table 3).
Fine-Scale Experimental Mapping of the PDZD2:GOLPH3
Duplication CNV
Experimental fine-scale mapping of the 5p13.3 duplication con-
firmed the extent of the CNV predicted by the discovery SNP mi-
croarray data from the last intron of the PDZD2 to the first intron
of the GOLPH3 genes, which are transcribed from the opposite
DNA strands (Fig. 3B). Subsequent sequencing of the breakpoint
junction-spanning region in the PDZD2:GOLPH3 duplication car-
riers refined the exact genomic coordinates of the CNV as Chr5:
32106204 – 32167777 and length as 61.6 kb (compared to 52.4 kb
based on SNP array estimation) (Fig. 3C). The presence of identical
recurrent tandem duplication was detected in all North European
carriers of the PDZD2:GOLPH3 CNV independent of the duplicon
copy number.
The flanking genomic context of the PDZD2:GOLPH3 duplica-
tion endpoints were characterized by a high number of repetitive
elements in the proximity and overlapping with both breakpoint
sites (Supp. Fig. S7). The proximal duplication endpoint was located
within the DNA repetitive sequenceMER1A and the distal endpoint
in the AluJb element, whereas no extensive DNA sequence homol-
ogy between the two repeat elements was observed. Also, no DNA
sequences leading to non-B DNA conformation were identified and
only amicrohomologyofonenucleotidewasdeterminedat the junc-
tion of the duplication endpoints by sequencing (Fig. 3D). Thus,
repeat-mediated rearrangement mechanisms other than nonallelic
homologous recombination have possibly contributed to the oc-
currence of this recurrent duplication (reviewed in [Hastings et al.,
2009]).
Expression Analysis of PDZD2 and GOLPH3 Genes in
Human Tissues Reveals the Highest Expression in Placenta
AlthoughGOLPH3wasubiquitously expressed in all tested tissues
(humanMTCpanels I and II), it exhibited thehighest transcript level
in the placenta (average expression relative to referenceHPRT, 2.99
± 0.06 SEM), followed by prostate, ovary, and leucocytes (relative
expression 1.50 ± 0.05, 1.13 ± 0.02, and 1.12 ± 0.04; respectively)
(Fig. 3E). In general, the level of PDZD2 transcripts was low in all
tissues; however, the highest expression was also determined for
the placenta exceeding fourfold the detected mRNA quantities in
the two other sites of highest expression, heart and ovary (relative
expression 1.33 ± 0.05 vs. 0.36 ± 0.01 and 0.34 ± 0.0, respectively)
(Fig. 3E). Overall, the expression profile of these genes points to
their functional relevance in the placenta and potentially in other
reproductive organs.
Discussion
In this study, we have addressed the effect of genome-wide CNVs
and contribution of selected CNV regions in modulating the pre-
disposition to RM. The genome-wide CNV profiling revealed a sig-
nificant enrichment of rearranged genes linked to innate immune
signaling and immunoregulatory interactions within the RM study
group, indicative of a potential effect on early pregnancy mainte-
nance. As amain result, we report a novel duplication locus at 5p13.3
conferring high risk of RM among the female subjects of both Esto-
nia and Denmark, and disrupting the PDZD2 and GOLPH3 genes
predominantly expressed in placenta and associated with pregnancy
maintenance for the first time.
The large cumulative burden of CNVs and specifically long dele-
tions may modify an individual’s predisposition to RM due to in-
creased chances of disrupting specifickey genesorpathways essential
for early pregnancymaintenance. A case-by-case analysis performed
in this study identified two RM cases RM-F4 and RM-M45 distin-
guished by heavy burden of CNVs and accumulation of several long
deletions in RM-F4 (n = 15 out of 19 CNVs; Fig. 2). Several potential
or known RM candidate genes that may independently or synergis-
tically elevate the risk of RM were rearranged within these cases,
including immunomodulatory loci such as 119 genes from the IGH
cluster and the previously reported RM-associated C4A and C4B
genes [Laitinen et al., 1991]. A subset of patients may thus exhibit
increased risk of RM disease attributable to excessive genomic bur-
den of CNVs; however, the finding remains to be confirmed by
future studies.
The detailed functional enrichment analysis of genes underCNVs
within the RM study group confirmed the highly specific overrepre-
sentation of pathways related to immune function and highlighted
the processes most sensitive to CNV alterations in early pregnancy
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Figure 3. Copy number distribution of the PDZD2:GOLPH3 duplication at 5p13.3 among female study subjects and experimental characterization
of the locus. A: Copy number distribution of the PDZD2:GOLPH3 CNV carriers and carrier frequency among female RM cases and female fertile
controls from Estonia and Denmark. CNV carriers have three to four copies of the duplication per genome in Estonia and three to more than four
copies per genome in Denmark (Supp. Fig. S2). Dup, duplication. B: Genomic context of 5p13.3 involving PDZD2 and GOLPH3 genes based on UCSC
database (hg19). The opposite transcription of the PDZD2 and GOLPH3 genes is indicated with blue and green arrows, respectively. DGV Struc
Var, structural variation data from the Database of Genomic Variants. C: Schematic representation of the 5p13.3 CNV locus with or without tandem
duplication. Experimentally confirmed duplication endpoints are indicated with red arrowheads and dotted lines. The breakpoint junction of the
tandem duplication is marked with red arrow tail and the breakpoint junction spanning region (5.8 kb) targeted with sequencing by primer walking
is indicated with black bar. Ex, exon. D: Alignment of the acquired DNA sequence of the duplication breakpoint junction to the sequences of the
proximal breakpoint region in PDZD2 intron 23 and distal breakpoint region in GOLPH3 intron 1. The microhomology of 1 bp determined at the
junction of the duplication endpoints (red arrow tail) is shown with bold red letter. E: Gene expression profile of the PDZD2 and GOLPH3 genes in
the human cDNA tissue panels. Expression level is given relative to the reference gene HPRT and as average of three amplification reactions ±
SEM. Gene expression levels in reproductive tissues are highlighted with gray bars. Each tissue sample is compiled of a pool of cDNAs (range, n =
2–98; Supp. Materials and Methods) with n = 8 for placenta, n = 15 for ovary, n = 98 for prostate, and n = 45 for testis sample.
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Table 3. 5p13.3 CNV Carrier Frequency among Estonian and Danish Control Individuals of This Study and in the Populations Reported in
the Database of Genomic Variants
CNV Number of
carriers carriers/study CNV CNV size
Populationa (%) group Phenotype Detection methodb type (kb) Reference
Dataset of this study
Denmark 1.7 2/115 Fertile controls TaqMan qPCR Dup 61.6 This study
Estonia 1.1 1/90 Fertile controls Illumina Human370CNV-Quad,
TaqMan qPCR
Dup 61.6 This study
Estonia 0.9 9/1,000 Cohort Illumina Human370CNV-Duo Dup 61.6 This study; Nelis
et al. (2009)
Dataset presented in the Database of Genomic Variants (DGV)
Ontario, Canadac 0.7 8/1,190 Cohort Affymetrix 500K and 100K Dup 35.1; 62d Zogopoulos et al.
(2007)
Worldwide (HGDP,
NINDS)e
1.1 21/1,854 Cohort; neurological
disease controls
Illumina HumanHap300,
Illumina HumanHap240S,
Illumina HumanHap650Y,
Illumina HumanHap550
Dup 68.1 Itsara et al. (2009)
Worldwide (HapMap,
PopGen)c,f
1.2 9/776 Healthy controls cohort Affymetrix 500K Dup 35.1; 95; 146d Pinto et al. (2007)
Philadelphia, PAc,g 1.0 20/2,026 Healthy controls cohort Illumina HumanHap550 V1 Dup 28.5; 38.9; 71.7d Shaikh et al. (2009)
aIn case of multiple studies targeting an identical study group (e.g., HapMap collection), results for the largest sample collection are presented.
bOnly carrier frequencies from studies applying SNP array copy number estimations are included from the DGV database.
cData for multiple overlapping nonrecurrent CNVs in 5p13.3 identified in the study are merged.
dCNV sizes of all overlapping CNVs in the region identified in the study.
eHGDP: cohort of the Human Genome Diversity Panel, 51 world populations, n = 1,064; NINDS, neurological disease controls of European descent from National Institute for
Neurological Disorders and Stroke, n = 790.
fHapMap: healthy individuals from four populations—parent–offspring trios of the Yoruba from Nigeria (YRI; n = 30), parent–offspring trios of European descent from Utah
(CEU; n = 30), unrelated Japanese from Tokyo, Japan (JPT; n = 45), and unrelated Han Chinese from Beijing, China (CHB; n = 45); PopGen: unrelated healthy individuals from
Northern Schleswig-Holstein (Northern Germany), n = 506.
gThe cohort included 1,492 unrelated individuals, 80 mother–father–child trios, 325 mother–child and 140 father–child duos, 59 siblings, and 10 twins.
Dup, duplication.
such as antigen binding, immunoregulatory interactions, innate im-
munity signaling, and complement cascade pathway associatedwith
RM previously (Table 1) [Li and Huang, 2009; Denny et al., 2013].
The CNVprofilemodifying the repertoire of presented antigens and
alloimmune responsesmay affect the subtle balance of the immuno-
logical tolerance at the fetomaternal interface. Asmother is carrying
a semiallogeneic fetus expressing paternally inherited alloantigens,
maternal immune rejection has been implicated in the etiology of
preeclampsia and RM previously [Wilczynski, 2006; Guleria and
Sayegh, 2007; Faridi and Agrawal, 2011]. The major contribution
of fetomaternal immune function in the development of RM has
also been demonstrated in gene expression profiling of thematernal
decidual tissue and chorionic villi of aborted fetuses [Baek et al.,
2002; Krieg et al., 2012].
As a major outcome of this study, a common multicopy du-
plication at 5p13.3 was identified conferring increased maternal
risk to RM in North European populations, Estonians and Danes
(meta-analysis OR = 4.82, P = 0.012). The prevalence of the
PDZD2:GOLPH3CNVwas detected withmore than fivefold higher
frequency in the female RM patients compared to fertile women
(6.6%–7.5% vs. 1.1%–1.7%) or worldwide population cohorts
(0.7%–1.2%; Tables 2 and 3). The largest effect ofGOLPH3:PDZD2
duplication as a risk factor was detected among the subgroup of
women diagnosed with primary RM (meta-analysis, OR = 5.86,
P = 0.007; Table 2). The duplication breakpoints of the identified
PDZD2:GOLPH3 recurrent CNV (61.6 kb in size) occurring in up
to >4 diploid copies (Fig. 3A) were positioned within the PDZD2
andGOLPH3 genes transcribed in the opposite directions (Fig. 3C).
Although the 5p13.3 duplication does not directly alter the copy
number of entire coding regions of the genes, the modifications in
the local genomic context may nevertheless interfere with the tran-
scription leading to dysregulation of the involved or neighboring
genes as reported previously [Henrichsen et al., 2009a, 2009b]. The
potential functional relevance of the identified rearrangement in
pregnancy was supported by the expression profiling of PDZD2 and
GOLPH3 in the human tissue panels revealing mutually high tran-
scription levels in the placenta (two to fourfold increase compared
to other tissues) but also in the maternal reproductive organ ovary
(Fig. 3E). We speculate that the significantly increased predisposi-
tion to RM among the female duplication carriers may be attributed
to the joint effect in maternal reproductive tissues and in the pla-
cental tissue carrying a maternally inherited duplication CNV. The
mechanism of action and joint effect of the 5p13.3 CNV remains to
be addressed further due to current limited availability of ovarian
and early miscarriage placental samples carrying the 5p13.3 CNV.
Most importantly, a recent study addressing the contribution of
maternal CNVs in cases of preeclampsia (PE)—a severe late preg-
nancy disorder originating from placental dysfunction—identified
the PDZD2:GOLPH3 duplication as the genetic risk factor of the
disease [Zhao et al., 2013]. The reported 50.4 kb duplication colo-
calized with the CNV identified in the current study and oc-
curred with the prevalence of 8.3% among the affected and 1.6%–
1.9% among unaffected female subjects. The identified risk to PE
(OR = 4.80, P < 0.05) is close to the effect detected for the RM
susceptibility in this study (Table 2). The possible common origin
of various pregnancy disorders has been acknowledged previously,
including overlapping causality of RM and PE [Li and Huang, 2009;
Baig et al., 2013]. Mutations in the dosage-sensitive gene GLUT3
(MIM# 138170) have been reported as the common genetic risk
factor leading to either early pregnancy loss or fetal growth restric-
tion [Ganguly et al., 2007]. Thus, it is plausible that the identified
PDZD2:GOLPH3 duplication may represent a pleiotropic risk fac-
tor in the genetic etiology of not only RM but also other pregnancy
complications.
Neither of the novel RM-associated genes PDZD2 or GOLPH3
has been linked to placental function or pregnancy maintenance
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previously. The function of PDZD2 is poorly defined and hasmainly
been addressed as a tumor suppressor [Yeung et al., 2003; Tam et al.,
2006]. More extensively studied conserved GOLPH3 is essential for
Golgi trafficking and maintenance of its structure [Dippold et al.,
2009; Wood et al., 2012]. Recently, genomic amplification of the
GOLPH3 gene was linked to oncogenic features [Scott et al., 2009;
Wang et al., 2012; Hu et al., 2013] and was shown to activate the
signaling pathway of mechanistic target of rapamycin (mTOR), an
essential component of mammalian reproductive function [Mu-
rakami et al., 2004; Wen et al., 2005; Busch et al., 2009; Yu et al.,
2011; Gonzalez et al., 2012; Tanwar et al., 2012]. Alterations in
mTOR signaling have been associated with multiple reproductive
disorders in mice and human, including RM [Roos et al., 2007; Ad-
hikari et al., 2010; Hirota et al., 2011; Leconte et al., 2011; Vatin
et al., 2012], thus providing the potential functional link between
the amplification of GOLPH3 and development of RM disease.
In summary, the findings of this study highlight the genetic het-
erogeneity of RM not only by characterizing the potential predis-
posing effect of the cumulative burden of genome-wide CNVs, but
also by identifying a common PDZD2:GOLPH3 duplication, as RM
risk factor detected in two independent North European sample
sets. Importantly, the identified PDZD2:GOLPH3 duplication may
represent a novel genetic risk factor for several pregnancy compli-
cations. The underlying functional effect of the PDZD2:GOLPH3
duplication in reproductive organs, placenta, and potentially in tu-
morigenesis remains to be addressed.
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